132 related articles for article (PubMed ID: 11358381)
21. Gene rearrangement of bcl-1 and bcl-2 is confined to distinct subgroups of high-grade malignant B-cell lymphomas.
Ott MM; Dahlheimer K; Müller-Hermelink HK; Feller AC
J Pathol; 1993 Mar; 169(3):303-7. PubMed ID: 8492222
[TBL] [Abstract][Full Text] [Related]
22. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack ER; Barber GN; Harrington WJ
Oncogene; 2001 Oct; 20(48):7029-40. PubMed ID: 11704827
[TBL] [Abstract][Full Text] [Related]
23. Expression of apoptosis regulators in germinal centers and germinal center-derived B-cell lymphomas: insight into B-cell lymphomagenesis.
Kondo E; Yoshino T
Pathol Int; 2007 Jul; 57(7):391-7. PubMed ID: 17587238
[TBL] [Abstract][Full Text] [Related]
24. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
25. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.
Yegappan S; Coupland R; Arber DA; Wang N; Miocinovic R; Tubbs RR; Hsi ED
Mod Pathol; 2001 Nov; 14(11):1147-56. PubMed ID: 11706077
[TBL] [Abstract][Full Text] [Related]
26. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells.
Strasser A; Harris AW; Cory S
Oncogene; 1993 Jan; 8(1):1-9. PubMed ID: 8423986
[TBL] [Abstract][Full Text] [Related]
27. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy.
Wissink EH; Verbrugge I; Vink SR; Schader MB; Schaefer U; Walczak H; Borst J; Verheij M
Radiother Oncol; 2006 Aug; 80(2):214-22. PubMed ID: 16916556
[TBL] [Abstract][Full Text] [Related]
28. [Molecular pathological characteristics of human B-cell lymphomas induced by Epstein-Barr virus].
Gan RL; Yin ZH; Liu TF; Dong BH; Zhou JG; Yao KT
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):925-9. PubMed ID: 14515211
[TBL] [Abstract][Full Text] [Related]
29. The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver.
Terradillos O; de La Coste A; Pollicino T; Neuveut C; Sitterlin D; Lecoeur H; Gougeon ML; Kahn A; Buendia MA
Oncogene; 2002 Jan; 21(3):377-86. PubMed ID: 11821950
[TBL] [Abstract][Full Text] [Related]
30. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
Duan H; Heckman CA; Boxer LM
Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
[TBL] [Abstract][Full Text] [Related]
31. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
[TBL] [Abstract][Full Text] [Related]
32. High expression of endogenous bcl-2 and bcl-xL in thymic lymphomas do not diminish their sensitivity to etoposide-induced apoptosis.
Matuszyk J; Kalas W; Cebrat M; Strzadala L
Anticancer Res; 2001; 21(4A):2677-80. PubMed ID: 11724338
[TBL] [Abstract][Full Text] [Related]
33. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneity of B-lymphoid tumors in E mu-myc transgenic mice.
Prasad VS; Temple MJ; Davisson MT; Akeson EC; Sidman CL
Cytometry; 1996 Feb; 23(2):131-9. PubMed ID: 8742172
[TBL] [Abstract][Full Text] [Related]
35. Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28).
Giri U; Terry NH; Kala SV; Lieberman MW; Story MD
Cancer Chemother Pharmacol; 2005 Jun; 55(6):511-21. PubMed ID: 15761769
[TBL] [Abstract][Full Text] [Related]
36. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas.
Loni L; Del Tacca M; Danesi R
Br J Cancer; 2001 Nov; 85(10):1425-31. PubMed ID: 11720423
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.
Arcinas M; Heckman CA; Mehew JW; Boxer LM
Cancer Res; 2001 Jul; 61(13):5202-6. PubMed ID: 11431360
[TBL] [Abstract][Full Text] [Related]
39. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
40. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
